前列腺癌
医学
Pet成像
前列腺
聚ADP核糖聚合酶
癌症研究
分子成像
癌症
核医学
放射性核素治疗
正电子发射断层摄影术
生化复发
PARP抑制剂
个性化医疗
肿瘤科
放射性核素显像
病理
医学影像学
显像剂
功能成像
癌症治疗
精密医学
靶向治疗
PCA3系列
作者
Zhao Yang,Wei Wang,Xuanyi Dai,Liya Wei,Y X Li,Wenfeng Gou,Feifei Xu
出处
期刊:Pharmaceuticals
[Multidisciplinary Digital Publishing Institute]
日期:2026-06-30
卷期号:19 (7): 1020-1020
摘要
Background/Objectives: Poly (ADP-ribose) polymerase (PARP), particularly PARP-1, is overexpressed in prostate cancer and linked to poor prognosis. PARP inhibitors show efficacy in homologous recombination deficiency (HRD)-positive tumors, but 30–70% of patients develop resistance, often due to low PARP expression. Tissue biopsies have limitations in assessing PARP levels, highlighting the need for noninvasive imaging tools. This study aimed to develop a novel [68Ga]Ga-PARP-targeted radiotracer for prostate cancer visualization and therapy monitoring, with potential implications for targeted radionuclide therapy. Methods: PET/CT imaging was conducted in 22RV1 prostate cancer xenograft-bearing mice using the [68Ga]Ga-FL9-7 probe. Imaging was performed at 1, 2, and 3 h post-injection. Standardized uptake values (SUV) were quantified to evaluate tumor and organ uptake, and tumor-to-normal tissue (T/NT) contrast ratios were calculated. Results: [68Ga]Ga-FL9-7 rapidly accumulated in tumors, with optimal imaging contrast achieved at 3 h post-injection. Normal organ uptake (e.g., kidneys) peaked at 1 h and subsequently declined, while tumor uptake increased over time. This differential clearance and retention resulted in the highest T/NT ratio at the 3 h time point. Conclusions: The [68Ga]Ga-FL9-7 probe enables effective noninvasive visualization of PARP-1 expression in prostate cancer, demonstrating clinical potential for tumor localization and monitoring of PARP-targeted therapies. This work also lays the groundwork for further development of PARP-targeted radionuclide therapy strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI